Castelnau Le Lez

This trial investigates the best antithrombotic treatment for patients with acute venous thromboembolism VTE who are also taking antiplatelet therapy due to a history of stable atherosclerotic cardiovascular disease. VTE and atherosclerotic cardiovascular disease share common risk factors and often occur together, requiring the use of anticoagulant and antiplatelet drugs. The study aims to compare the benefits and risks of two treatment strategies to address concerns about bleeding and cardiovascular events in these patients. Participants will be randomly assigned to one of two groups. The experimental group will receive full-dose anticoagulant therapy alone, stopping antiplatelet therapy. The control group will continue combined full-dose anticoagulant and antiplatelet therapies, including aspirin or clopidogrel. Anticoagulant treatment will be given according to international guidelines for deep vein thrombosis DVT or pulmonary embolism PE, and treatment duration will be up to 12 months. During the study, participants will be monitored for clinically relevant bleeding, recurrent VTE, and major adverse ischemic cardiovascular and cerebrovascular events MACCE. Researchers will evaluate safety and effectiveness across these outcomes at the end of the treatment period. Secondary measures include non-major bleeding, arterial events, and VTE complications. The study involves regular assessments over up to one year to determine which treatment strategy offers the best overall clinical benefit.

Researchers are studying chronic kidney disease patients who are starting dialysis to understand how certain bone mineral markers relate to the progression of vascular calcification over two years. The study focuses on non-traditional cardiovascular risk factors that may impact patients heart health during this period. Participants will have their plasma levels of osteoprotegerin and fibroblast growth factor 23 measured, along with a vascular calcification score assessed by X-ray of the lateral abdominal aorta. Cardiovascular events will also be recorded throughout the two-year follow-up to evaluate changes and risks. During the study, patients will undergo blood tests and imaging to monitor these markers and calcification progression. Researchers will track cardiovascular events and analyze the data to see how initial marker levels relate to vascular changes. The total participation lasts two years, during which patients receive regular assessments and monitoring.

Researchers are evaluating a new anti-regurgitation infant formula to see how well it reduces regurgitation episodes and improves digestive tolerance in infants with gastroesophageal reflux. This is a randomized, controlled, double-blind trial comparing the new formula to a standard thickened formula. The study is sponsored by United Pharmaceuticals and focuses on infants between 2 weeks and 4 months old. The study includes two groups one receiving the new formula thickened with fibers and the other receiving a formula thickened with locust bean gum. The trial lasts for 1 month and 2 days, starting with a 2-day pre-selection period followed by a 30-day follow-up. Participants can optionally continue for an additional 2 months of follow-up from day 30 to day 90. During the study, infants will be monitored for the frequency and severity of regurgitations, digestive symptoms like diarrhea and constipation, feeding behaviors, sleep quality, and growth measurements including weight, length, head circumference, and BMI. Parents and investigators satisfaction will also be recorded. These assessments occur at days 14, 30, and 90. The primary outcome is the frequency of regurgitation at day 14. All study visits and evaluations are conducted under careful monitoring to track safety and treatment effects.

This trial studies adults aged 18 to 60 with Acute Myeloid Leukemia AML to improve overall survival using risk-adapted treatment strategies. It is an open-label, multicenter phase IIIII study evaluating different chemotherapy regimens during induction, consolidation, and, when applicable, stem cell transplantation. The study also assesses graft versus host disease GvHD prevention methods after transplant in intermediate-risk patients. Participants receive one of several chemotherapy induction regimens comparing daunorubicin and high-dose idarubicin combined with cytarabine. Consolidation treatment compares high-dose versus intermediate-dose cytarabine, sometimes combined with drugs like vosaroxin, dexamethasone, or venetoclax. For patients receiving allogeneic stem cell transplant, GvHD prophylaxis is studied comparing standard treatments such as methotrexate and cyclosporine with mycophenolic acid combinations. Treatment cycles and doses vary based on the patients risk and response. Throughout the study, participants undergo bone marrow evaluations, blood tests, and heart function assessments to monitor response and safety. Researchers track overall survival over three years, incidence of acute GvHD within 100 days post-transplant, and disease-free survival at 18 months. Participants provide informed consent and are monitored regularly during treatment and follow-up periods. The study completion is planned for January 2032.